Across TCGA pan-cancer cohorts, SFT2D2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SFT2D2 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SFT2D2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SFT2D2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where SFT2D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.889	.013	20	view →
PDAC	OS	Median	All	0.901	0.803	.017	17	view →
LSCC	OS	Tertile	All	0.928	1.000	.019	7	view →
HNSC	DFS	Median	All	0.735	0.524	.011	6	view →
LUAD	OS	Quartile	All	1.000	0.947	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SFT2D2 tumor-vs-normal RNA expression · all SFT2D2 data types